Cencora, Inc. (NYSE:COR) Shares Sold by Archford Capital Strategies LLC

Archford Capital Strategies LLC trimmed its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 28.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,554 shares of the company's stock after selling 4,495 shares during the quarter. Archford Capital Strategies LLC's holdings in Cencora were worth $3,213,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in COR. Cornerstone Wealth Group LLC acquired a new position in Cencora during the first quarter worth $635,000. Retirement Guys Formula LLC increased its stake in shares of Cencora by 7.6% during the first quarter. Retirement Guys Formula LLC now owns 6,663 shares of the company's stock worth $1,853,000 after purchasing an additional 471 shares in the last quarter. Ledyard National Bank raised its position in shares of Cencora by 14.1% during the 1st quarter. Ledyard National Bank now owns 8,923 shares of the company's stock worth $2,481,000 after purchasing an additional 1,101 shares during the last quarter. AssuredPartners Investment Advisors LLC raised its position in shares of Cencora by 5.6% during the 1st quarter. AssuredPartners Investment Advisors LLC now owns 2,920 shares of the company's stock worth $812,000 after purchasing an additional 154 shares during the last quarter. Finally, Asset Management One Co. Ltd. lifted its stake in Cencora by 6.8% in the 1st quarter. Asset Management One Co. Ltd. now owns 105,637 shares of the company's stock valued at $29,377,000 after buying an additional 6,755 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the transaction, the chief executive officer now directly owns 47,582 shares in the company, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman now owns 311,913 shares of the company's stock, valued at $91,271,982.06. This trade represents a 4.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,127 shares of company stock worth $9,812,296 over the last three months. Insiders own 10.80% of the company's stock.

Cencora Trading Up 1.5%

NYSE COR traded up $4.38 on Thursday, reaching $296.70. 1,645,496 shares of the company were exchanged, compared to its average volume of 1,517,030. The company has a current ratio of 0.87, a quick ratio of 0.52 and a debt-to-equity ratio of 6.01. The business's fifty day moving average price is $289.70 and its 200 day moving average price is $264.56. The stock has a market capitalization of $57.51 billion, a P/E ratio of 34.42, a price-to-earnings-growth ratio of 1.46 and a beta of 0.58. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.80 EPS. Analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.74%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Morgan Stanley set a $288.00 price objective on Cencora in a research note on Tuesday, April 15th. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Finally, Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $306.91.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.